Clinical trialCLINICALTRIALSToday
Researchers in France are looking for 9,000 patients with three rare types of skin cancer: Merkel cell carcinoma, advanced basal cell carcinoma, and adnexal tumors of the skin. This study will collect information about how these cancers develop, how they respond to treatment, and how they affect patients' lives. The goal is to better understand these uncommon cancers so doctors can improve care in the future.
WHY IT MATTERSIf you have been diagnosed with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma, you may be eligible to join this large French national study that could help shape future treatment approaches for these poorly understood skin cancers.
Clinical trialCLINICALTRIALSMay 13
Researchers are testing a drug called osimertinib to see if it can help people with a specific type of lung cancer after surgery. This cancer has uncommon changes in a gene called EGFR. The study includes 51 patients and is checking whether the drug is safe and effective when given after the cancer is surgically removed.
WHY IT MATTERSIf you have non-small cell lung cancer with an uncommon EGFR mutation and have had surgery, this trial is testing a targeted drug that may reduce your risk of cancer returning — but the trial is no longer accepting new patients.
Clinical trialUNITERAREMay 13
Researchers are testing a new treatment approach for clear cell renal cell carcinoma, a type of kidney cancer. The study combines two types of drugs: immunotherapy (which helps your immune system fight cancer) and a targeted therapy drug (TKI) that blocks specific cancer growth signals. This trial is now accepting patients and will test whether giving these drugs before and after surgery helps patients live longer.
WHY IT MATTERSThis trial is now recruiting patients with clear cell renal cell carcinoma at a major Chinese hospital — if you have this kidney cancer diagnosis, you may be eligible to access experimental combination treatment before standard treatment options.
Clinical trialUNITERAREMay 1
Researchers are looking for kidney cancer patients whose tumors shrank significantly or disappeared after immunotherapy treatment. This new trial will study whether removing the original kidney after successful immunotherapy helps prevent the cancer from coming back. The study starts in May 2026 and is currently accepting patients.
WHY IT MATTERSThis trial offers metastatic renal cell carcinoma patients who achieved complete or major response to immunotherapy a chance to participate in research that could determine whether surgical removal of the primary kidney improves long-term outcomes.
Clinical trialCLINICALTRIALSApr 28
Researchers are testing a new drug called Sutetinib Maleate Capsule to treat advanced lung cancer in patients who have specific uncommon mutations in their cancer cells. This is a Phase 2 study, which means the drug has already been tested for safety in a small group and now researchers want to see how well it works in a larger group of about 99 patients. The study is currently accepting new participants at multiple hospitals.
WHY IT MATTERSThis trial offers access to a targeted therapy specifically designed for patients with non-small cell lung cancer carrying rare EGFR mutations (L861Q, G719X, S768I) who may have limited treatment options.
Clinical trialCLINICALTRIALSApr 24
Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.
WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.